Search results
Showing 201 to 250 of 1835 results for carers
This guideline covers the organisation and provision of major trauma services in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by providing a systematic approach to the delivery of major trauma care. It does not cover services for people with burns.
Referral points to virtual wards are similar to traditional models of care. Our guidance and advice can help you decide where to provide care and what to consider.
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Information for family members or carers: What information and support are needed by family members or carers of people...
Unintentional injuries: prevention strategies for under 15s (PH29)
This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.
In development Reference number: GID-TA11115 Expected publication date: TBC
In development Reference number: GID-TA11531 Expected publication date: TBC
This quality standard covers the diagnosis and management of constipation of unknown cause in babies, children and young people (from birth to 18 years). It describes high-quality care in priority areas for improvement.
View quality statements for QS62Show all sections
Sections for QS62
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: First-line treatment with laxatives
- Quality statement 3: Reviewing disimpaction therapy
- Quality statement 4: Reviewing maintenance therapy
- Quality statement 5: Written information
- Quality statement 6: Referral if no response to treatment
- Update information
prescribing for patients dying in their usual place of residence, on patient and carer reported symptoms at end of life? Any explanatory...
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
In development Reference number: GID-TA11561 Expected publication date: 11 March 2026
In development Reference number: GID-TA11576 Expected publication date: 18 June 2026
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
In development Reference number: GID-TA11643 Expected publication date: 18 March 2026
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life). Any explanatory...
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Awaiting development Reference number: GID-TA11565 Expected publication date: 21 May 2026
This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.
View quality statements for QS55Show all sections
Sections for QS55
- Quality statements
- Quality statement 1: Multidisciplinary teams for young people
- Quality statement 2: Access to clinical trials
- Quality statement 3: Electronic prescribing of chemotherapy
- Quality statement 4: Psychological and social support
- Quality statement 5: Neuro-rehabilitation
- Quality statement 6: Follow-up and monitoring of late effects
- Quality statement 7: Fertility support
standard principles of infection prevention and control that patients and carers experience in their own homes? Any explanatory notes(if...
In development Reference number: GID-TA11772 Expected publication date: 03 September 2026
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
In development Reference number: GID-TA11508 Expected publication date: 29 July 2026
In development Reference number: GID-TA11599 Expected publication date: TBC
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
In development Reference number: GID-TA11802 Expected publication date: TBC
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Question What are the information and support needs of parents and carers with babies on parenteral nutrition? Any explanatory notes(if...
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
In development Reference number: GID-TA11484 Expected publication date: TBC
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1: Objective tests to support diagnosis
- Quality statement 2: Documented personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
View quality statements for QS83Show all sections
Sections for QS83
Devices for remote monitoring of Parkinson's disease (HTG657)
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.
effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments? Any explanatory notes(if...
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation
In development Reference number: GID-IPG10416 Expected publication date: 25 February 2026
In development Reference number: GID-TA11424 Expected publication date: 07 May 2026
In development Reference number: GID-TA11405 Expected publication date: TBC
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
In development Reference number: GID-TA11334 Expected publication date: TBC
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.
In development Reference number: GID-TA11633 Expected publication date: 18 June 2026
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]
In development Reference number: GID-TA11628 Expected publication date: 11 March 2026
Interventions with fathers and male carers:- What interventions are effective and cost effective when working with fathers and male...